Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Growth in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totalling 6,500 shares, a growth of 27.5% from the September 30th total of 5,100 shares. Based on an average trading volume of 11,300 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Pulmatrix in a report on Friday. They issued a “hold” rating for the company.

Pulmatrix Stock Up 1.0 %

Shares of NASDAQ PULM opened at $2.02 on Monday. The business has a fifty day moving average price of $2.06 and a two-hundred day moving average price of $2.03. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The company had revenue of $1.55 million during the quarter.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.